Dylan Van Haaften

GENMAB NEUTRAL | DKK2150 Darza continues to drive the beat and raise, Epco filing drawing near.

Genmab released 2Q after a pre-announcement of improved guidance (~8% for FY) earlier this week, the midpoint of guidance is already near consensus expectations, and results feature nothing new in terms of sales trends with Darza (1LMM) continuing on a strong trajectory with Kesimpta (2L MS), and Tepezza (TED). We continue to believe epcoritamab sales are likely too bullish given the options and complexity in 1L/2L DLBCL/NHL. We re-iterate Neutral and DKK2150 target price.
Genmab A/S

Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.

Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Dylan Van Haaften

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch